<DOC>
	<DOCNO>NCT00002814</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy use paclitaxel topotecan , plus G-CSF , treat patient glioblastoma multiforme anaplastic astrocytoma refractory recurrent .</brief_summary>
	<brief_title>Combination Chemotherapy Patients With Brain Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate patient refractory recurrent glioblastoma multiforme anaplastic astrocytoma treat paclitaxel ( TAX ) topotecan ( TOPO ) granulocyte colony-stimulating factor ( G-CSF ) support . II . Determine survival patient . III . Describe toxicity TAX/TOPO/G-CSF . IV . Evaluate tumor p53 expression relation response TAX/TOPO/G-CSF . OUTLINE : All patient receive paclitaxel , topotecan , G-CSF every 3 week least 2 course 2 course beyond maximum response . Patients follow every 3 month 2 year , every 6 month relapse survival . PROJECTED ACCRUAL : A total 35 patient enter 1-3 response first 20 patient .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Biopsy proven glioblastoma multiforme anaplastic astrocytoma Central pathologic review DartmouthHitchcock Medical Center , include assay tumor p53 expression No anaplastic oligodendroglioma No mixed oligodendroastrocytoma Recurrent progressive disease follow radiotherapy document CT MRI within 2 week entry PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60 % 100 % Hematopoietic : WBC least 3,000 ANC least 1,500 Platelets least 100,000 Hepatic : Bilirubin great 1.0 mg/dL AST/ALT great 2.5 time normal Renal : Creatinine great 1.5 mg/dL Other : No documented sensitivity E. coliderived product No major medical psychiatric illness would interfere therapy compliance schedule followup No pregnant nursing woman Adequate contraception require fertile patient PRIOR CONCURRENT THERAPY : No prior taxanes topoisomerase I inhibitors At least 4 week since chemotherapy ( 6 week since nitrosoureas ) At least 4 week since radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>